TSO3 Inc.

Equities

TOS

CA8730151013

Delayed Toronto S.E. Other stock markets			5-day change	1st Jan Change
- ^CAD	-.--%		+0.59%	+12.50%

2019	9402-4874 Québec Inc. completed the acquisition of TSO3 Inc..	CI
2019	Tso3 Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	CI

TSO3 Sets Second Quarter Earnings Call for Wednesday, August 2, 2017 at 8:30 a.m. EDT

July 24, 2017 at 04:14 pm EDT

Québec City, July 24, 2017 - TSO Inc. (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, will hold a conference call on Wednesday, August 2, 2017, to discuss its financial results for the second quarter ended June 30, 2017. Financial results will be issued in a press release prior to the call.

TSO President and CEO R.M. (Ric) Rumble and CFO Glen Kayll, will host the conference call, followed by a question and answer period.

Date: Wednesday, August 2, 2017

Time: 8:30 a.m. Eastern Daylight Time (5:30 a.m. PDT)

Toll-free dial-in number: 1-888-231-8191

International dial-in number: 1-514-807-9895 (Montreal); 1-647-427-7450 (Toronto)

Conference ID: 1472312

Analysts and institutional investors are invited to participate on the call. Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact CMA at 1-949-432-7566.

Other interested parties may listen to the live webcast of the conference call at

http://event.on24.com/r.htm?e=1472312&s=1&k=ED81A2C58567EF69CD449BC9A08BBE24 which will be available for replay in the Investors section of the Company's website at www.tso3.com.

About TSO

Founded in 1998, TSO's activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. TSOalso offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.

For more information about TSO, visit the Company's website at www.tso3.com

- 30 -

Source: TSO Inc.

For further information

Company Contacts:

TSOInc., R.M. (Ric) Rumble, President and CEO, Tel: 418 651-0003, Email: info@tso3.com

TSO Inc., Glen Kayll, CFO, Tel: 418 651-0003, Email: info@tso3.com

Investor Relations:

Capital Market Access LLC, Ron Both, 949-432-7557, Email: tos@cma.team

Renmark Financial Communications Inc., Barry Mire, Tel: 416 644-2020 or 514 939-3989, Email: bmire@renmarkfinancial.com

TSO3 Inc. published this content on 24 July 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 24 July 2017 20:14:07 UTC.

Original documenthttp://www.tso3.com/en/news_events/article/189

Public permalinkhttp://www.publicnow.com/view/A18CA91EF51314B53CE5B4DBDD9ED830F6136FDE

Latest news about TSO3 Inc.

9402-4874 Québec Inc. completed the acquisition of TSO3 Inc..	19-09-30	CI
Tso3 Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-12	CI
9402-4874 Québec Inc. entered into a definitive arrangement agreement to acquire TSO3 Inc. for CAD 40.6 million.	19-08-11	CI
TSO3 Inc. Announces Group Purchasing Agreement with Capstone Health Alliance	19-06-11	CI
Transcript : TSO3 Inc., Q1 2019 Earnings Call, May 07, 2019	19-05-07
Tso3 Inc. Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-06	CI
TSO3 Inc. Announces Board Changes	19-04-02	CI
Transcript : TSO3 Inc., Q4 2018 Earnings Call, Mar 28, 2019	19-03-28
Tso3 Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2018	19-03-27	CI
TSO3 Inc. Reports Write Down of Tangible and Intangible Assets for the Fourth Quarter Ended December 31, 2018	19-03-26	CI
TSO3 Inc. Auditor Raises 'Going Concern' Doubt	19-03-26	CI
TSO3 Expands Duodenoscope Sterilization Testing	19-03-14	CI
TSO3 Inc. Announces the Results of the Company’S Clinical In-Use and Simulated Use Testing of the Terminal Sterilization of Duodenoscopes	19-01-30	CI
TSO3 Inc. Announces the Results of the Clinical In-Use and Simulated Use Testing of the Terminal Sterilization of Duodenoscopes	18-11-15	CI
Transcript : TSO3 Inc., Q3 2018 Earnings Call, Nov 07, 2018	18-11-07
TSO3 Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2018	18-11-06	CI
TSO3 Inc. Wins Contract	18-10-30	CI
TSO3 Inc.(TSX:TOS) dropped from S&P Global BMI Index	18-09-24	CI
TSO3 Inc. Appoints Martin J. Madden to the Board of Directors	18-08-29	CI
TSO3 Inc. Joins with Uchealth in Announcing the First Patient Procedure in Colorado Performed with Duodenoscope Sterilized Using the STERIZONE® Technology	18-08-20	CI
Transcript : TSO3 Inc., Q2 2018 Earnings Call, Aug 08, 2018	18-08-08
TSP3 Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2018	18-08-07	CI
TSO3 Inc. Announces Closing of USD 20 Million Financing with Courage Capital	18-08-06	CI
Getinge and TSO3 Ends Exclusive Distribution Agreement on Low Temperature Sterilization	18-08-01	CI
TSO3 Inc. announced that it has received $20 million in funding	18-07-31	CI

Chart TSO3 Inc.

Duration

Period

More charts

Company Profile

TSO3 Inc is a Canada-based company engaged in the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment. The Company's products are used in the sterilization departments of hospital and other medical facilities. It also provides services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes. It has developed a sterilizer using a sterilization process based on ozone as the sterilizing agent. The Company's STERIZONE VP4 Sterilizer is a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide (H2O2) and ozone (O3) as its sterilants. The STERIZONE VP4 terminally sterilizes multiple channels in a single device.

Sector

More about the company